Freedom Capital downgraded Amgen (NASDAQ:AMGN) from a “strong-buy” to a “hold” rating. This comes despite several other analysts recently issuing “outperform” or “buy” ratings with increased price targets for the biotechnology company. Amgen’s stock opened at $369.19, has a market cap of $198.80 billion, and recently reported strong quarterly earnings, exceeding analyst expectations, with its FY 2026 guidance forecasting 21.600-23.000 EPS.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Amgen (NASDAQ:AMGN) Downgraded to "Hold" Rating by Freedom Capital
Freedom Capital downgraded Amgen (NASDAQ:AMGN) from a “strong-buy” to a “hold” rating. This comes despite several other analysts recently issuing “outperform” or “buy” ratings with increased price targets for the biotechnology company. Amgen’s stock opened at $369.19, has a market cap of $198.80 billion, and recently reported strong quarterly earnings, exceeding analyst expectations, with its FY 2026 guidance forecasting 21.600-23.000 EPS.